HALEOS LABS
|
HALEOS LABS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 57.26 | 66.51 | 30.08 | 37.91 | 83.76 |
| CEPS(Rs) | 110.04 | 111.56 | 70.34 | 73.32 | 116.78 |
| DPS(Rs) | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
| Book NAV/Share(Rs) | 706.34 | 650.15 | 584.84 | 557.71 | 503.53 |
| Tax Rate(%) | 29.35 | 28.47 | 35.74 | 31.43 | 22.70 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.77 | 11.66 | 9.21 | 8.05 | 8.88 |
| EBIT Margin(%) | 8.34 | 9.04 | 5.93 | 6.55 | 10.02 |
| Pre Tax Margin(%) | 6.62 | 6.77 | 2.90 | 4.63 | 8.42 |
| PAT Margin (%) | 4.68 | 4.84 | 1.87 | 3.18 | 6.51 |
| Cash Profit Margin (%) | 8.75 | 8.72 | 6.27 | 6.19 | 9.08 |
| Performance Ratios | |||||
| ROA(%) | 4.14 | 4.72 | 1.60 | 2.98 | 7.54 |
| ROE(%) | 8.68 | 10.03 | 3.66 | 7.09 | 17.98 |
| ROCE(%) | 10.53 | 12.60 | 7.42 | 9.44 | 18.42 |
| Asset Turnover(x) | 0.89 | 0.97 | 0.85 | 0.94 | 1.16 |
| Sales/Fixed Asset(x) | 1.13 | 1.29 | 1.19 | 1.56 | 2.28 |
| Working Capital/Sales(x) | 55.72 | 45.48 | 31.65 | 14.02 | 18.89 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.89 | 0.78 | 0.84 | 0.64 | 0.44 |
| Receivable days | 62.42 | 56.67 | 52.44 | 40.71 | 31.92 |
| Inventory Days | 70.62 | 70.10 | 90.14 | 87.15 | 68.75 |
| Payable days | 151.10 | 135.79 | 143.42 | 146.47 | 135.85 |
| Valuation Parameters | |||||
| PER(x) | 20.95 | 16.24 | 22.57 | 13.71 | 8.30 |
| PCE(x) | 10.90 | 9.68 | 9.65 | 7.09 | 5.95 |
| Price/Book(x) | 1.70 | 1.66 | 1.16 | 0.93 | 1.38 |
| Yield(%) | 0.13 | 0.14 | 0.22 | 0.29 | 0.22 |
| EV/Net Sales(x) | 1.41 | 1.19 | 0.99 | 0.80 | 0.81 |
| EV/Core EBITDA(x) | 9.94 | 8.19 | 8.60 | 7.88 | 7.80 |
| EV/EBIT(x) | 14.78 | 11.70 | 14.99 | 10.72 | 7.26 |
| EV/CE(x) | 1.46 | 1.46 | 1.10 | 0.94 | 1.23 |
| M Cap / Sales | 1.09 | 0.95 | 0.67 | 0.50 | 0.60 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -3.17 | 12.67 | -3.04 | -9.86 | 31.81 |
| Core EBITDA Growth(%) | -5.50 | 42.54 | 9.88 | -12.07 | 13.25 |
| EBIT Growth(%) | -9.21 | 73.84 | -14.28 | -39.78 | 61.21 |
| PAT Growth(%) | -4.98 | 196.03 | -44.38 | -55.03 | 86.62 |
| EPS Growth(%) | -13.91 | 121.15 | -20.68 | -54.73 | 86.79 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.51 | 0.43 | 0.55 | 0.59 | 0.51 |
| Current Ratio(x) | 1.04 | 1.06 | 1.07 | 1.19 | 1.14 |
| Quick Ratio(x) | 0.55 | 0.61 | 0.53 | 0.56 | 0.55 |
| Interest Cover(x) | 4.85 | 3.99 | 1.96 | 3.42 | 6.26 |
| Total Debt/Mcap(x) | 0.30 | 0.26 | 0.48 | 0.63 | 0.37 |
Compare Financial Ratios of peers of HALEOS LABS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| HALEOS LABS | ₹464.1 Cr | -0.1% | 0.3% | 16.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹421,539.0 Cr | -1.4% | -6.6% | 7.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹247,576.0 Cr | 1.2% | -2.6% | 60% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹177,251.0 Cr | -2% | -6.1% | 33% | Stock Analytics | |
| CIPLA | ₹105,290.0 Cr | -2.3% | -5.8% | -13.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,752.6 Cr | -1.1% | 3.8% | -5.5% | Stock Analytics | |
HALEOS LABS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| HALEOS LABS | -0.1% |
0.3% |
16.2% |
| SENSEX | 0.8% |
-4.8% |
-10.5% |
You may also like the below Video Courses
